Impact of preformed donor-specific antibodies against HLA class I on kidney graft outcomes: Comparative analysis of exclusively anti-Cw vs anti-A and/or -B antibodies

Table 3 Analysis of possible predictors of acute antibody-mediated rejection occurrence by univariable Cox regression

	HR for AMR	95%CI	P
Recipient
Age (yr), per year	0.96	0.89-1.03	0.269
Female (vs male) gender	0.26	0.05-1.26	0.094
Retransplant	2.18	0.52-9.13	0.287
Previous blood transfusions	0.5	0.12-2.10	0.345
Previous pregnancies	0.24	0.03-1.99	0.187
Donor
Age (yr), per year	1.01	0.96-1.06	0.684
Living donor	1.79	0.22-14.76	0.588
Pretransplant immunological data
Peak PRA, per unit	1.01	1.00-1.03	0.149
DSA Cw (vs AB)	0.6	0.12-2.99	0.537
DSAsum MFI, per 10001	1.07	1.01-1.15	0.034
Transplant
ABDR HLA mismatches, per unit	0.84	0.50-1.41	0.512
ATG (vs basiliximab) induction	1.68	0.34-8.34	0.527
FCXM + (n = 29)	0.75	0.09-6.21	0.787
Desensitized	1.2	0.24-5.97	0.825
Delayed graft function	2.55	0.61-10.68	0.201

¹Only independent predictor identified by multivariable Cox regression model (all variables included) using backward elimination (P-value < 0.050 needed for retention in the model). DSA: Donor-specific antibodies; AMR: Acute antibody-mediated rejection; MFI: Mean fluorescence intensity; ATG: Anti-thymocyte globulin; FCXM: Flow cytometry crossmatch.